vs
Side-by-side financial comparison of Diamondback Energy (FANG) and Zoetis (ZTS). Click either name above to swap in a different company.
Diamondback Energy is the larger business by last-quarter revenue ($3.4B vs $2.4B, roughly 1.4× Zoetis). Zoetis runs the higher net margin — 25.3% vs -43.2%, a 68.4% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -9.0%). Over the past eight quarters, Diamondback Energy's revenue compounded faster (23.1% CAGR vs 4.4%).
Diamondback Energy, headquartered in Midland, Texas, is an American company engaged in hydrocarbon exploration in the Permian Basin.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
FANG vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.4B | $2.4B |
| Net Profit | $-1.5B | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | -82.4% | 31.9% |
| Net Margin | -43.2% | 25.3% |
| Revenue YoY | -9.0% | 3.0% |
| Net Profit YoY | -235.8% | 3.8% |
| EPS (diluted) | $-4.99 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.4B | $2.4B | ||
| Q3 25 | $3.9B | $2.4B | ||
| Q2 25 | $3.7B | $2.5B | ||
| Q1 25 | $4.0B | $2.2B | ||
| Q4 24 | $3.7B | $2.3B | ||
| Q3 24 | $2.6B | $2.4B | ||
| Q2 24 | $2.5B | $2.4B | ||
| Q1 24 | $2.2B | $2.2B |
| Q4 25 | $-1.5B | $603.0M | ||
| Q3 25 | $1.0B | $721.0M | ||
| Q2 25 | $699.0M | $718.0M | ||
| Q1 25 | $1.4B | $631.0M | ||
| Q4 24 | $1.1B | $581.0M | ||
| Q3 24 | $659.0M | $682.0M | ||
| Q2 24 | $837.0M | $624.0M | ||
| Q1 24 | $768.0M | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | -82.4% | 31.9% | ||
| Q3 25 | 31.5% | 37.0% | ||
| Q2 25 | 31.0% | 36.7% | ||
| Q1 25 | 41.3% | 36.5% | ||
| Q4 24 | 38.0% | 31.6% | ||
| Q3 24 | 26.8% | 36.6% | ||
| Q2 24 | 46.6% | 33.0% | ||
| Q1 24 | 50.2% | 34.1% |
| Q4 25 | -43.2% | 25.3% | ||
| Q3 25 | 25.9% | 30.0% | ||
| Q2 25 | 19.0% | 29.2% | ||
| Q1 25 | 34.7% | 28.4% | ||
| Q4 24 | 28.9% | 25.1% | ||
| Q3 24 | 24.9% | 28.6% | ||
| Q2 24 | 33.7% | 26.4% | ||
| Q1 24 | 34.5% | 27.4% |
| Q4 25 | $-4.99 | $1.37 | ||
| Q3 25 | $3.51 | $1.63 | ||
| Q2 25 | $2.38 | $1.61 | ||
| Q1 25 | $4.83 | $1.41 | ||
| Q4 24 | $3.40 | $1.29 | ||
| Q3 24 | $3.19 | $1.50 | ||
| Q2 24 | $4.66 | $1.37 | ||
| Q1 24 | $4.28 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.0M | — |
| Total DebtLower is stronger | $13.7B | — |
| Stockholders' EquityBook value | $37.0B | $3.3B |
| Total Assets | $71.1B | $15.5B |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $104.0M | — | ||
| Q3 25 | $159.0M | $2.1B | ||
| Q2 25 | $219.0M | $1.4B | ||
| Q1 25 | $1.8B | $1.7B | ||
| Q4 24 | $161.0M | $2.0B | ||
| Q3 24 | $370.0M | $1.7B | ||
| Q2 24 | $6.9B | $1.6B | ||
| Q1 24 | $896.0M | $2.0B |
| Q4 25 | $13.7B | — | ||
| Q3 25 | $15.8B | — | ||
| Q2 25 | $15.1B | — | ||
| Q1 25 | $13.0B | — | ||
| Q4 24 | $12.1B | — | ||
| Q3 24 | $11.9B | — | ||
| Q2 24 | $12.0B | — | ||
| Q1 24 | $6.6B | — |
| Q4 25 | $37.0B | $3.3B | ||
| Q3 25 | $39.1B | $5.4B | ||
| Q2 25 | $38.9B | $5.0B | ||
| Q1 25 | $38.5B | $4.7B | ||
| Q4 24 | $37.7B | $4.8B | ||
| Q3 24 | $37.4B | $5.2B | ||
| Q2 24 | $17.4B | $5.0B | ||
| Q1 24 | $16.9B | $5.1B |
| Q4 25 | $71.1B | $15.5B | ||
| Q3 25 | $76.2B | $15.2B | ||
| Q2 25 | $71.9B | $14.5B | ||
| Q1 25 | $70.1B | $14.1B | ||
| Q4 24 | $67.3B | $14.2B | ||
| Q3 24 | $65.7B | $14.4B | ||
| Q2 24 | $35.6B | $14.2B | ||
| Q1 24 | $29.7B | $14.3B |
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | 0.39× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | 0.39× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3B | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3B | $893.0M | ||
| Q3 25 | $2.4B | $938.0M | ||
| Q2 25 | $1.7B | $486.0M | ||
| Q1 25 | $2.4B | $587.0M | ||
| Q4 24 | $2.3B | $905.0M | ||
| Q3 24 | $1.2B | $951.0M | ||
| Q2 24 | $1.5B | $502.0M | ||
| Q1 24 | $1.3B | $595.0M |
| Q4 25 | — | $732.0M | ||
| Q3 25 | — | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $455.0M |
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 20.8% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% | ||
| Q1 24 | — | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 2.34× | 1.30× | ||
| Q2 25 | 2.40× | 0.68× | ||
| Q1 25 | 1.68× | 0.93× | ||
| Q4 24 | 2.18× | 1.56× | ||
| Q3 24 | 1.83× | 1.39× | ||
| Q2 24 | 1.83× | 0.80× | ||
| Q1 24 | 1.74× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FANG
| Oil Explorationand Production | $2.7B | 81% |
| Oil Purchased | $308.0M | 9% |
| Natural Gas Liquids Production | $293.0M | 9% |
| Natural Gas Production | $4.0M | 0% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
